#Canada #Toronto #Cardiol Therapeutics #MAVERIC trial #CardiolRx™

Cardiol Therapeutics Achieves Enrollment Milestone in MAVERIC Trial

In a significant development, Cardiol Therapeutics Inc. has successfully met its enrollment target for the MAVERIC trial ahead of schedule. Originally aiming to recruit 110 patients, the company accomplished this milestone by September 23, 2026. This achievement signals a promising progression in the ongoing evaluation of CardiolRx™, a therapeutic candidate aimed at reducing recurrence risks in patients suffering from recurrent pericarditis.

The MAVERIC Steering Committee has recommended an expansion of the trial's enrollment from 110 to 150 patients. This decision is aimed at ensuring a robust analysis of the drug’s effectiveness following encouraging initial findings. A preliminary review indicated that the rate of recurring pericarditis among patients receiving treatment was lower than anticipated, suggesting a potentially favorable outcome for CardiolRx™. David Elsley, the President and CEO of Cardiol Therapeutics, expressed optimism regarding the trial's progress, emphasizing that the current findings were unexpected but encouraging. He noted the importance of this additional enrollment to uphold the necessary statistical power for the trial’s efficacy evaluation.

What’s Next for CardiolRx™?

As the trial progresses, the company anticipates unveiling topline results by mid-2027. This timeline reflects a slight adjustment from earlier estimates that predicted results would be available in the first quarter of 2027. With sufficient funding to support the MAVERIC trial through early 2028, Cardiol is well-positioned to see this critical study through to completion.

MAVERIC aims to evaluate CardiolRx™'s impact on delaying or preventing the recurrence of pericarditis. The primary endpoint focuses on the time until the first new episode occurs, which will be assessed alongside secondary endpoints measuring the percentage of patients who remain free from new attacks by the end of the study.

The Importance of the MAVERIC Program

Cardiol Therapeutics is dedicated to advancing treatments for heart diseases, with CardiolRx™ at the forefront of its portfolio. The drug works by modulating the inflammasome pathway, a critical component in the body’s innate immune response that is implicated in inflammation and fibrosis related to pericarditis, myocarditis, and heart failure.

The MAVERIC program is particularly significant given the debilitating nature of recurrent pericarditis, which can severely impact patients' quality of life. Symptoms typically include intense chest pain, shortness of breath, and extreme fatigue, often resulting in emergency medical visits or hospitalizations.

With the U.S. FDA granting Orphan Drug Designation to CardiolRx™ for the treatment of both recurrent and acute pericarditis, the company is committed to providing innovative and effective therapeutic solutions for patients afflicted by these conditions.

In addition to the MAVERIC trial, Cardiol is exploring further applications for CardiolRx™ through its ARCHER Program that focuses on acute myocarditis, linking it to heart failure and sudden cardiac deaths, particularly in younger populations.

Future Prospects

As this pivotal trial unfolds, the clinical landscape for treating recurrent pericarditis may witness a transformative shift, thanks to the rigorous research and development efforts led by Cardiol Therapeutics. With the potential to address a significant unmet need in cardiac health, CardiolRx™ may soon play a crucial role in managing this challenging condition, ultimately improving patient outcomes and quality of life.

For those interested in keeping track of upcoming results and advancements, further information can be found on Cardiol Therapeutics’ official website.